DOCSLIB.ORG

Biocon Biologics Is Talking to Several Governments for Ways to Disintermediate the Supply of Insulin

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biocon Biologics Is Talking to Several Governments for Ways to Disintermediate the Supply of Insulin Biocon Limited THE ANNUAL REPORT 2020 Touching a billion lives through MANIFESTO affordable innovation 1 THE IMPACT MANIFESTO ANNUAL REPORT 2020 Biocon Limited Transforming lives through meaningful impact Sharp inequities in access have denied the benefits from advances in medical science to almost a third of the world’s population. Hefty price tags on life-saving drugs have created unbearable financial burden for patients in most of the world. Inadequate research spending has led to a fragile medical innovation ecosystem with serious repercussions on global preparedness for health emergencies. The vulnerability of healthcare systems worldwide to a global pandemic stands exposed. 2 THE IMPACT MANIFESTO ANNUAL REPORT 2020 Biocon Limited Biocon is leveraging its affordable innovation model to reduce disparities in access to safe, high-quality medicines, as well as, address the gaps in scientific research to find innovative solutions to impact a billion lives. Take a quantum leap in serving the needs of our patients through innovative solutions that go beyond the product. Transform patient lives through the introduction of therapies that improve treatment outcomes while enhancing their health and well-being. Dramatically improve patient survival and, if possible, cure hitherto incurable diseases through advanced targeted therapies. Put the care back in healthcare by pursuing a humanitarian path to ensure better patient care and outcomes while reducing costs through our ‘high-quality, low cost, high volume’ business model. ANNUAL REPORT 2020 THE IMPACT MANIFESTO 3 Biocon Limited The Biocon Manifesto We seek to leverage differentiated technologies to transform healthcare by ensuring access to affordable, quality assured, complex therapies that significantly improve patient outcomes and are available to all. Our roadmap for the future is to enable a healthier world. As a committed stakeholder of the global health agenda under the UN Sustainable Development Goals (SDGs), Biocon has drawn up a manifesto to deliver on its commitment to universal healthcare. 4 THE IMPACT MANIFESTO ANNUAL REPORT 2020 Biocon Limited accessibility Use our science, scale and expertise to enhance access to essential drugs for patients on the lowest rung of the economic ladder Uncover new medical insights aimed at expanding the scope of therapy to address unmet needs affordability Focus on the kind of innovation that adds the condition of affordability to accessibility Bring competition for expensive innovator medicines through our generics and biosimilars availability Build strategic global and regional partnerships to make high-quality biopharmaceuticals available to the maximum number of people Create a robust portfolio of ‘blockbuster’ drugs with the potential to benefit a billion patients assurance Demonstrate the highest levels of ethics, compliance and governance Assure continuous supply of high-quality products conforming to international regulatory standards ANNUAL REPORT 2020 THE IMPACT MANIFESTO 5 Biocon Limited Business Highlights At Biocon, we have concluded yet another in key markets. We also made strategic meaningful year, breaking new ground, investments, brought new partners on crossing new milestones and delivering board, entered new markets, received high-quality biopharmaceuticals to regulatory approvals, expanded production millions worldwide. capacity, added to our expertise and We made significant headway in the unlocked value for our stakeholders. commercialization of multiple products generics Crossed an annual revenue milestone of `20,000 million novel molecules for the first time Started global clinical trials for our first-in-class oral insulin molecule, Extended footprint to China Insulin Tregopil, in Type 1 diabetes through a licensing deal for 3 Generic Formulations Clinical trials initiated by partner Filed new Drug Master Files and Equillium to study our novel equivalents for multiple APIs anti-CD6 molecule, Itolizumab, in Lupus Nephritis and severe Asthma Started construction of a greenfield, fermentation-based Started a clinical trial in India manufacturing facility in Andhra to study Itolizumab in treating Pradesh, India to cater to moderate to severe patients with anticipated growth in APIs business COVID-19 complications 6 THE IMPACT MANIFESTO ANNUAL REPORT 2020 Biocon Limited biologics Touched the lives of 2.1 million patients Insulin Glargine (Australia) through through access to our biosimilars our partner Mylan Initiated value unlocking of Biocon Received regulatory clearances from Biologics through private equity both U.S. and EU regulators for investment for a minority stake, our Insulin Glargine manufacturing indicating an equity valuation of facility in Malaysia USD 3 billion Expanded R&D footprint through Committed to enable universal the acquisition of R&D capital access to rh-Insulin at less than assets to set up a 60,000 sq. ft. 10 U.S. cents / day in low- and world-class integrated R&D middle-income countries in the facility in Chennai run-up to the insulin centenary Enhanced production capacity Expanded commercial footprint for Drug Substance and Drug of key biosimilars: Pegfilgrastim Product for key biosimilars through (Australia, Canada), Trastuzumab brownfield and greenfield projects (U.S., Australia, Canada) and research services Commissioned new research facilities in Bengaluru and Hyderabad Commenced qualification of API manufacturing facility in Mangaluru Extended biologics discovery and preclinical research capabilities in CAR-T therapy, an innovative cell-based approach to treating cancer Received Good Laboratory Practice (GLP) certification for viral testing facility from the NGCMA, making it India’s first and only GLP-certified viral clearance study service provider Repurposed a high-end laboratory to conduct RT-PCR tests for COVID-19 Partnered with Pune-based Mylab to supply reagents for use in its indigenously developed COVID-19 testing kits ANNUAL REPORT 2020 THE IMPACT MANIFESTO 7 Biocon Limited FY20 at a Glance Revenue Profit for the year* EBITDA Margin 65,286 7,482 27 � Million � Million % R&D Spend (Gross) Employees (Total) EPS 5,271 12,000+ 6.3 � Million � *includes exceptional items Business revenue mix Small Molecules Biologics Research Services 20,937 19,513 20,119 � Million � Million � Million 8% 2% Branded Others Formulation 31% Small Molecules 22% 78% Domestic Branded Formulations International 30% 29% Research Biologics 5,362 Services � Million Business Revenue Contribution Geographic Distribution #includes inter-segment revenue 8 THE IMPACT MANIFESTO ANNUAL REPORT 2020 Biocon Limited Contents 10 Chairperson’s Review 16 CEO’s Message 20 Financial FAQs 25 Financial Highlights 28 Board of Directors OUR BUSINESSES 34 Generics 42 Novel Biologics 44 Scientific Advisory Board 46 Branded Formulations 47 Biosimilars – Biocon 61 Research Biologics Services – Syngene 61 SUSTAINABILITY 69 Environment 72 People 75 Social Biocon Foundation Biocon Academy FINANCIAL REPORTS Scan the QR code to 87 Board’s Report download the Annual Report on your mobile device. 127 Management Discussion and Analysis 148 Corporate Governance Report 169 Business Responsibility Report 181 Standalone Financial Statements 243 Consolidated Financial Statements Visit us at: www.biocon.com Follow us on Twitter: @bioconlimited @BioconBiologics ANNUAL REPORT 2020 THE IMPACT MANIFESTO 9 Biocon Limited Chairperson's Review Kiran Mazumdar-Shaw Executive Chairperson 10 THE IMPACT MANIFESTO ANNUAL REPORT 2020 Biocon Limited On a mission to impact a billion lives Dear Shareholders, Biocon’s philosophy of affordable innovation to make life-saving medicines accessible to everyone, anywhere on the planet, has never been more relevant than it is today. We are in the throes of a global pandemic and the world is looking up to the healthcare industry to develop vaccines, treatments, diagnostics and products that will see it through the COVID-19 crisis. The novel coronavirus outbreak has demonstrated that if humanity is to survive as a species, it is imperative that there is equitable access to all essential health products and technologies without distinction of race, religion, political belief and economic or social condition. Universal access to quality healthcare for all is non-negotiable. In the fight against COVID-19, low- and middle-income countries (LMICs) seem to be faring better than wealthier, better-resourced, developed nations. With this change in dynamics, we are likely to witness greater reciprocity and sharing of best practices between LMICs and high-income countries (HICs) leading to genuine bi-directional partnerships. As well established business models are dismantled and long-held assumptions The novel dispelled, we could see healthcare being reshaped and democratized around coronavirus the planet. outbreak has The future will call for a new approach to prevention, screening, diagnosis, demonstrated therapy, monitoring and management of disease. Demand for therapies that that universal are patient-focused, data-driven and digitally enabled will increase. Patient care access to quality will move to non-clinical settings driven by technology and connectivity, even as healthcare accelerated adoption of digital therapeutics empowers patients with for all is point-of-care management. non-negotiable. Greater application of Artificial Intelligence (AI) and Machine Learning will make drug discovery and development more innovative, cheaper and faster. Efficient capacity creation and productivity optimization will be critical
Load more

Recommended publications
  • Sl No. Reg No. NAME and ADDRESS 1 Reg No.17478 Reg No 9415 Shri Yallappa Dhulikoppa S/O Basavalingappa No
    Sl No. Reg No. NAME AND ADDRESS 1 Reg No.17478 Reg No 9415 Shri Yallappa Dhulikoppa S/o Basavalingappa No. 40, Chikkadasarahalli, Neriga Post, Sarjapur Hobli, Bangalore-562 125 M-98804-88772 2 Reg No.17479 Reg No 9770 Shri Ambareesha D No. 79, Megha Hospet, Bhayasabi Layout, Vivekanand Cross, Anekal, Bangalore-562 106 M-90086-75889 3 Reg No.17480 Reg No.11914 Shri B.R.Nandeesh Aradhya No.68/2, 'Basaveshwara Nilaya' Vidyanagar, 4th Cross, Bommasandra Industrial Area Tq-Anekal, Bangalore-560 099 Mo-99867-18414 E- [email protected] 4 Reg No.19604 Reg No 12890 Shri Muddaveerappa S/o Channapparadhya At-Hilalalige (Gate) Post-Chandapur, Attibele Hobli Tq-Anekal, Bangalore North Mo-9449648129 5 Reg No.24386 Reg No 12930 Shri Purushotham Y.R. S/o H.N.Rudramuniyappa Mahadeshwara Stores, H.N.R. Comples, Yadavanahalli Gate Attibele Hobli, Tq-Anekal Bangalore-562107 Mo- 9916970059 6 Reg No.24388 Reg No 12931 Shri Arun Aradhya M S/o Mallikarjuna At & Post-Yadavanahalli-562 107 Attibele Hobli, Tq-Anekal, Bangalore Mo- 9900776813 7 Reg No.27985 Reg No.13438 Shri Sharanabasava Hiremath S/o H.M.Siddaiah S.M.M.Enterprises, Gopalareddy Building Near Canara Computer, Vinayakanagar, Tirupalya Road, Hebbagodi Bangalore-560 099 Mo- 9880545450 8 Reg No.2360 Reg No.13439 Shri Basavaraja Moke S/o Jambanna Moke Sharma Building, Gollahalli Road, Near S.B.I.(ATM) Hebbagodi Bangalore-560 099 Mo-9945975209 9 Reg No.2361 Reg No.13440 Shri Ravi Chandra E S/o Eshwarappa Susheelamma Building, Vinayakanagar Hebbagodi Bangalore-560 099 Mo-9880610078 10 Reg No.11711 Reg No.13441 Shri Veeresh Lalasangi S/o Shivaputrappa NO.52, Balappa Reddy Building Vinayakanagar Hebbagodi Bangalore-560 099 Mo-9739476464 11 Reg No.11712 Reg No.13442 Smt Dhakshayini L.K.
    [Show full text]
  • Biocon Annual Report 2014
    Annual Report 2014 Tryst and Trust Tryst and Trust Annual Report Biocon Limited 20th KM Hosur Road, Electronic City, Bangalore – 560 100, India T – 91 80 2808 2808 2014 E – corporate.communications@ biocon.com W – www.biocon.com Forward Looking Statement In this Annual Report we have disclosed forward-looking information to enable investors to comprehend our prospects and take informed investment decisions. This report and other statements - written and oral - that we periodically make contain forward-look- ing statements that set out anticipated results based on the management’s plans and assumptions. We have tried wherever possible to identify such statements by using words such as ‘anticipates’, ‘estimates’, ‘expects’, ‘projects’, ‘intends’, ‘plans’, ‘believes’ and words of similar substance in connection with any discussion of future performance. The market data & rankings used in the various chapters are based on several published reports and internal company assessment. We cannot guarantee that these forward looking statements will be realised, although we believe we have been prudent in our assumptions. The achievement of results is subject to risks, uncertainties and even inaccurate assumptions. Should known or unknown risks or uncertainties materialise, or should underlying assumptions prove inaccurate, actual res- ults could vary materially from those anticipated, estimated or projected. Readers should bear this in mind. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new
    [Show full text]
  • To View BMRCL Annual Report 2019-20
    I N D E X 1. Board of Directors ............................................................................................................ 2 2. Notice of AGM ................................................................................................................. 4 3. Chairman’s Speech ........................................................................................................... 6 4. Board’s Report ................................................................................................................. 9 5. Independent Auditor’s Report ....................................................................................... 66 6. Comments of the Comptroller and Auditor General of India......................................... 82 7. Balance Sheet as at 31st March, 2020............................................................................. 84 8. Statement of Profit and Loss for the year ended 31st March, 2020 ............................... 86 9. Cash Flow Statement for the year ended 31st March, 2020 ........................................... 90 10. Notes to the Financial Statements ................................................................................. 92 1 BOARD OF DIRECTORS Shri Durga Shanker Mishra Chairman, BMRCL & Secretary - Ministry of Housing and Urban Affairs, Government of India Shri Ajay Seth Managing Director, BMRCL Shri Jaideep Director, BMRCL &OSD (UT) and Ex-Officio Joint Secretary, Ministry of Housing and Urban Affairs, Government of India Shri K. K. Saberwal Director, BMRCL
    [Show full text]
  • Ten Stock Picks Under 10X P/E
    Ten stock picks under 10x P/E April 2020 April 3, 2020 Ten stock picks under 10x P/E… It is a Déjà vu (a feeling of having already experienced the present situation) all over again as markets have a tendency, once in a decade, of creating declines of high magnitude and velocity in a very short span of time. This always leaves the investors in a iffy kind of a situation as to whether the world is coming to an end. However, on the contrary, if one thinks rationally, markets also implicitly offer a lot of dislocated opportunities if one seizes them with patience and holds with conviction. Thus, they can generate alpha over a period of time. Hence, to capture one such Déjà vu feeling, we are recommending stocks across large caps, midcaps and small caps space, PICK MOMENTUM which have currently undergone a massive correction on account of the current uncertain environment. The underlying thesis of these stocks is: • Established business models that have survived such panic situations many a time with a credible management at the helm. All the stocks in our recommended universe are trading at or around 10x P/E on FY22E basis • The companies have a steady balance sheet with no leverage and a credible history of generating positive cash flows across business cycles. The RoCE of such companies (>15%) is sufficient to cover their cost of capital and create incremental economic value added or EVA • The companies are consistent dividend distributors. The dividends earned in rough times like these, to some extent, will help to cover the opportunity cost of holding such stocks.
    [Show full text]
  • Motherson Sumi Systems Companyname
    RESULT UPDATE MOTHERSON SUMI SYSTE MS Strong quarter; looking beyond FY21 India Equity Research| Automobiles COMPANYNAME Motherson Sumi’s (MSS) Q4FY20 EBITDA at INR13.9bn surpassed our and EDELWEISS 4D RATINGS consensus estimates ~40% driven by sharp gross margin improvement Absolute Rating BUY and overall sharpened cost focus. While near-term outlook remains hazy, Rating Relative to Sector Outperform the COMPANYNAME company is well placed to benefit from: 1) Faster-than-expected Risk Rating Relative to Sector High recovery in developed markets. 2) Cost reduction initiatives as volumes Sector Relative to Market Overweight recovers. 3) Strong FCF generation as the peak capex cycle is behind. Management is targeting USD33-35bn revenue over the next five years, which includes ~25% contribution from non-automobile segments MARKET DATA (R: MOSS.BO, B: MSS IN) (aerospace, defence, healthcare, logistics, etc). However, given the near- CMP : INR 102 Target Price : INR 117 term uncertainties, we are adjusting our FY21/22E EPS -40%/+3%. 52-week range (INR) : 151 / 49 Maintain ‘BUY’ with revised TP of INR117 (INR96 earlier) as we roll over Share in issue (mn) : 3,157.7 valuations to FY22E. M cap (INR bn/USD mn) : 322 / 8,113 Avg. Daily Vol.BSE/NSE(‘000) : 11,087.5 Q4FY20: Strong operating performance after long Consolidated revenue of INR151bn (down 12.0% YoY) was ~5% below our estimate. SHARE HOLDING PATTERN (%) However, strong improvement in gross margin (up 240bps YoY) due to product mix and Current Q3FY20 Q2FY20 cost control efforts translated into EBITDA margin of 9.2% (up ~200bps YoY), ahead of Promoters * 61.7 61.7 61.7 our 6.0% estimate.
    [Show full text]
  • Hero Motocorp Exchange Offer
    Hero Motocorp Exchange Offer Augustin brines his gadoids trawls knowledgably, but duckier Vasilis never dart so polemically. Is Ulric thyroid or cod when skiatrons some firers bounce pizzicato? Realisable Mitchael desponds baggily. Lcd display that further, there are connected features and exchange offer hefty discounts on Stocks to watch Airtel Future Retail SBI Hero MotoCorp Jubilant Food. Justdial is priced at the spark plugs are used for hero motocorp share. Privacy settings. Hero MotoCorp has great festive offers on quote Hero bikes along with attractive bike. Download vanguard newspapers or the exchange. Motorcycle Market 2021 Global Share Size Future Demand. Hero honda exchange offer QuikrBikes India. Hero MotoCorp Adds Glitter To Festive Season Exchange. Hero MotoCorp Limited NSE National Stock system of. Equity indices subdued auto stocks suffer ANI News. MarketBuzz Podcast With Reema Tendulkar Sensex Nifty. Hero Super Splendor User Reviews Milage is walking for god drive Good commuter bike on upper range of price And it mind also gives a regular mileage with minimum service cost. Hero MotoCorp GAIL India Bajaj Auto HDFC Life BPCL and NTPC. Share Market LIVE Updates Sensex Nifty Edge Lower. Motherson Sumi Hero MotoCorp and Ashok Leyland led the. Hero Wars Vip Points. Hero motocorp bs4 online booking Pravoorgmk. Do share price page button is offering exchange offers are the. If the side stand and hyderabad, phone numbers mentioned before investing resources from exchange offer. 4050 results for hero honda exchange made in QuikrBikes India 411 Results on 19 February 2021 Featured Sort by Most Popular Recently Posted Lowest. Hero MotoCorp hits 100m units Vanguard News.
    [Show full text]
  • Women Achievers 2011
    Women Achievers i TABLE OF CONTENTS Introduction iii Message v Foreword vi NEELAM DHAWAN 1 PRIYA CHETTY RAJAGOPAL 2 SUCHITRA K ELLA 4 SUDHA IYER 5 ANURADHA SRIRAM 6 AKILA KRISHNAKUMAR 8 KIRAN MAZUMDAR SHAW 9 DEEPTI REDDY 10 REKHA M MENON 11 REVATHI KASTURI 13 SANDHYA VASUDEVAN 15 Dr VILLOO MORAWALA PATEL 16 AMUKTA MAHAPATRA 18 Dr REKHA SHETTY 19 YESHASVINI RAMASWAMY 21 BEENA KANNAN 23 BINDU ANANTH 24 PARVEEN HAFEEZ 25 MALLIKA SRINIVASAN 26 SUSHMA SRIKANDTH 27 SHEELA KOCHOUSEPH 29 HASTHA KRISHNAN 30 HEMALATHA RAJAN 31 HEMA RAVICHANDAR 32 KAMI NARAYAN 34 UMA RATNAM KRISHNAN 35 SHALINI KAPOOR 37 PREETHA REDDY 38 ii Women Achievers Dr. THARA SRINIVASAN 40 AKHILA SRINIVASAN 42 RAJANI SESHADRI 43 SHOMA BAKRE 44 SANGITA JOSHI 45 GAYATHRI SRIRAM 46 JAYSHREE VENKATRAMAN 48 GEETANJALI KIRLOSKAR 49 KALPANA MARGABHANDU 50 SHARADA SRIRAM 51 SAMANTHA REDDY 53 SHOBHANA KAMINENI 54 VINITA BALI 56 RAJSHREE PATHY . 58 GEETHA VISWANATHAN 59 VALLI SUBBIAH 60 RANJINI MANIAN 62 VANITA MOHAN 63 TILISA GUPTA KAUL 64 SHARAN APPARAO 65 SUNEETA REDDY 66 VANAJA ARVIND 67 Dr. KAMALA SELVARAJ 69 SAKUNTALA RAO 70 NEETA REVANKER 71 MAURA CHARI 73 HAMSANANDHI SESHAN 75 MAHIMA DATLA 77 Dr. NIRMALA LAKSHMAN 78 NANDINI RANGASWAMY 79 PRITHA RATNAM 81 Dr. THARA THYAGARAJAN 82 REVATHY ASHOK 83 SANGITA REDDY 85 GEEHTA PANDA 87 Women Achievers iii INTRODUCTION In the last two decades Indian women have entered work force in large numbers and many of them hold senior positions now Gone are the days when we hardly saw women in lead- ership positions in organizations Some of India’s
    [Show full text]
  • Auto, IT Firms Lead Growth Surge
    ADVANCE TAX COLLECTION Auto, IT firms lead growth surge SHRIMI CHOUDHARY such as State Bank of India (SBI) and KEY CONTRIBUTORS New Delhi, 22 June ICICI Bank reported lower (but dou- Amount paid (in ~ cr) YoY growth (%) ble-digit) growth in tax payment. Maruti Suzuki 150 200 Tech Mahindra 190 35 Sharp growth in advance tax payment According to officials, the first- by India Inc has been led mainly by quarter numbers have been compared Hero Motocorp 126 96 SBI 1,910 21 automakers and technology giants with the beginning of the pandemic- TCS 1,160 65 HUL 397 20 including Maruti Suzuki, Hero induced lockdown, so automatically L&T 30 50 Cipla 126 20 MotoCorp, Tata Consultancy (TCS), the figures showed a sharp jump. The and Infosys. second instalment will have a clearer P&G 32 45 NTPC 485 10 These four companies reported a picture, they said. Infosys 720 44 Dr Reddy’s 60 9 jump between 44 per cent and 200 per Meanwhile, final advance tax col- ICICI Bank 800 39 HDFC Bank 2,100 8 cent in the April-June quarter of this lection by companies showed 51 per financial year on account of a low base. cent growth (YoY) for the first quarter. Note: Figures for April 1-June 21 Source: CBDT sources Even top financial institutions Turn to Page 13 > > FROM PAGE 1 Auto, IT firms lead growth surge Earlier, the preliminary data impact on the companies’ increased its tax outflow by Suzuki paid ~150 crore. showed a growth rate of 146 growth. 35 per cent at ~190 crore.
    [Show full text]
  • Office of the Additional Director General of Foreign Trade, Bengaluru
    OFFICE OF THE ADDITIONAL DIRECTOR GENERAL OF FOREIGN TRADE, BENGALURU EXPORT HOUSE DETAILS FOR THE PERIOD 2015-20 EXPORT HOUSE CERTIFICATES ISSUED IN 2016-17 01 0797003967 HILLTOP STONES PRIVATE LIMITED., 1 Star 2020 A/5911 dtd. NO.1/18,1/19,1/4-1,1/4- 25.04.2016 3,BANNERGHAT TA ROAD,NEAR MICO BACK GATE BANGALORE-560030 02 0788004549 JINDAL ALUMINIUM LTD 2 Star 2020 A/5906 dtd. 16 TH K M TUMKUR ROAD 20.04.2016 BANGALORE -560073 03 0793017289 KARLE INTERNATIONAL PVT LTD 2 Star 2020 B/2860 dtd. NO.151, INDL. SUBURB, 19.05.2016 YESHWANTHPUR, BANGALORE- 560022 04 0789009269 ANGLO-FRENCH DRUGS & 1 Star 2020 A/5916 dtd. INDUSTRIES LTD 19.05.2016 41,3RD CRS.BLOCK V, RAJAJINAGAR, BANGALORE-560010 05 0788000250 STERLING FOODS 2 Star 2020 B/2861 dtd. MILAGRES CENTRE,2ND 01.06.2016 FLR.HAMPANKATTA, MANGALORE- 575001 06 0794012094 SREEDEVI CASHEW INDUSTRIES 2 Star 2020 B/2859 dtd. MUDAR, BAJAGOLI, KARKALA TALUK, 19.05.2016 UDUPI, KARNATAKA-574122 07 0388038047 ABB LIMITED 3 Star 2020 C/1622 dtd. BRIGADE GATEWAY CAMPUS, 26/1, 13.05.2016 DR.RAJKUMAR ROAD, MALLESHWARAM, BANGALORE- 560055 08 0788000560 BIOCON LIMITED, 3 Star 2020 JB/0710 dtd. 20TH K M, HOSUR ROAD, 05.04.2016 ELECTRONIC CITY P.O, BANGALORE -560100 09 0700016031 SKF TECHNOLOGIES INDIA PVT LTD 1 Star 2020 A/5907 dtd. PLOT NO.2 BOMMASANDRA INDL 21.04.2016 AREA,BANGALORE -560099 10 0701004461 KENMORE SHOES PVT LTD 2 Star 2020 B/2857 dtd. GOVINDAPURAM MAIN 19.05.2016 ROAD,NAGAWARA BANGALORE-560045 11 0793003580 ARON UNIVERSAL LTD 1 Star 2020 A/5914 dtd.
    [Show full text]
  • Biocon Biologics Joins Hands with IDF in Its Mission to Promote Diabetes Care, Prevention and Effective Management Worldwide”
    Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com February 16, 2021 To, To, The Manager The Manager BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corporate Communication Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai – 400 001 Mumbai – 400 050 Scrip Code – 532523 Scrip Symbol - Biocon Subject: Press Release titled “Biocon Biologics Joins Hands with IDF in its Mission to Promote Diabetes Care, Prevention and effective Management Worldwide”. Dear Sir/Madam, Please find enclosed the press release titled “Biocon Biologics Joins Hands with IDF in its Mission to Promote Diabetes Care, Prevention and effective Management Worldwide”. The above information will also be available on the website of the Company at www.biocon.com. Kindly take the same on record and acknowledge. Thanking You, Yours faithfully, For Biocon Limited _______________ Mayank Verma Company Secretary and Compliance Officer PRESS RELEASE Biocon Biologics Joins Hands with IDF in its Mission to Promote Diabetes Care, Prevention and effective Management Worldwide First Biosimilar Insulin Company to Partner with International Diabetes Federation (IDF) Bengaluru, Karnataka; INDIA: February 16, 2021 Biocon Biologics Ltd., a fully integrated ‘pure play’ biosimilars company and a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), is pleased to partner with The International Diabetes Federation (IDF) as the first biosimilar insulin company to promote and support IDF’s Core Mission initiative and activities. This important partnership with IDF coincides with the start of the centenary celebrations of the discovery of insulin and takes forward Biocon Biologics’ mission of enabling affordable access to insulins to people with diabetes worldwide.
    [Show full text]
  • Auto Yearbook FY20
    AutoAuto Yearbook FY20 April 30, 2020 Section I: Update – What went down? FY20 was a tough year for the entire Indian automotive industry. Myriad demand and supply side issues continued to trouble the space, continuing the system-wide weakness that set in around the 2018 festive period. Broad- based decline in OEM volumes (Exhibit 1) throughout the year encapsulated the pain at that level as well as the knock-on impact on supporting Report ecosystems of ancillaries, on the one hand, and dealerships, on the other. Higher cost incidence and general reluctance in consumer spending affected the PV and 2-W segments most, while slowing economic activity and system pecial overcapacity took a toll on CV segment. OEM focus on inventory destocking S in the run up to BS-VI switchover from April 2020 and Covid-19 outbreak were other issues that adversely impacted Q4FY20, in particular. Total industry volumes fell 14.8% YoY to 2.63 crore – one of the worst performances in decades, with all major segments registering hefty declines- PV - Down 14.8% YoY to 34.53 lakh units, was dragged by 19.9% dip in passenger cars and 39% decline in vans. UV sub segment, however, posted 2.7% growth courtesy several successful new Research Analysts product launches CV – Was hardest hit, down 29.7% YoY to 7.78 lakh units. M&HCV Shashank Kanodia, CFA [email protected] sub segment dropped 43.3% amid persistent weakness in trucks (down 49.1%) while buses bucked the trend (up 3.5%). LCV sub Jaimin Desai [email protected] segment came off by 20.7% with both – passenger and goods categories in the red 3-W – Was down 10.2% YoY to 11.39 lakh units amid double digit declines in passenger as well as goods categories 2-W – Was down 14.4% YoY to 2.1 crore units.
    [Show full text]
  • Adagio Therapeutics Partners with Biocon Biologics to Bring Potent
    Adagio Therapeutics Partners with Biocon Biologics to Bring Potent and Broadly Neutralizing COVID-19 Antibody Treatment to Patients in India and Select Emerging Markets Waltham, MA – July 26, 2021 – Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced a partnership agreement with Biocon Biologics Ltd., to combat the ongoing COVID-19 crisis in southern Asia. Biocon Biologics Ltd. is a fully integrated biosimilars company and a subsidiary of Biocon Ltd., a global biopharmaceuticals company, (BSE code: 532523, NSE: BIOCON). Under the terms of the agreement, Adagio will provide Biocon with materials and know-how to manufacture and commercialize an antibody treatment based on ADG20 in India and additional select emerging markets. ADG20, Adagio’s lead product candidate, is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 as either a single or combination agent. Unlike other antibody-based therapies specifically targeting SARS-CoV-2, ADG20 has demonstrated an ability to neutralize SARS-CoV-2 in non-clinical studies, including variants of concern, as well as a broad range of other SARS-like viruses. ADG20 is currently being evaluated in two separate Phase 2/3 global clinical trials, the STAMP trial to evaluate ADG20 for the treatment of non-hospitalized COVID-19 patients and the EVADE trial to evaluate ADG20 for the prevention of COVID-19. “This partnership underscores the commitment of two companies to come together in order to make a significant impact on global health,” said Tillman Gerngross, Ph.D., co-founder and chief executive officer of Adagio.
    [Show full text]